key: cord-0737909-ktkcjv26
authors: OSMAN, I. O.; Menelotte, C.; Brouqui, P.; MILLION, M.; LAGIER, J.-c.; PAROLA, P.; STEIN, A.; LA SCOLA, B.; MEDDEB, L.; MEGE, J.-L.; RAOULT, D.; DEVAUX, C. A.
title: Expression of ACE2 receptor, soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin (1-7), is modulated in COVID-19 patients.
date: 2021-02-10
journal: nan
DOI: 10.1101/2021.02.08.21251001
sha: 8e3df4e946b71a509f0d028b5dfc2289d4ef61ad
doc_id: 737909
cord_uid: ktkcjv26

Although SARS-CoV-2 is primarily a pulmonary-tropic virus, it is nonetheless responsible for multi-organ failure in patients with severe forms of COVID-19, particularly those with hypertension or cardiovascular disease. Infection requires virus binding to the angiotensin I converting enzyme 2 (ACE2) monocarboxypeptidase, a regulator of blood pressure homeostasis through its ability to catalyze the proteolysis of Angiotensin II (AngII) into Ang(1-7). Although assumed, it had not been proven so far whether the SARS-CoV-2 replication in COVID-19 patients could modulate the expression of the ACE2 receptor and/or the AngII plasma levels. We demonstrate here, that in COVID-19 patients the ACE2 mRNA expression is markedly reduced in circulating blood cells. This ACE2 gene dysregulation mainly affects the monocytes which also show a lower expression of membrane ACE2 protein. Moreover, a significant decrease in soluble ACE2 plasma levels is observed in COVID-19 patients, whereas the concentration of sACE2 returns to normal levels in patients recovered from COVID-19. In the plasma of COVID-19 patients, we also found an increase in AngI and AngII. On the other hand, the plasma levels of Ang(1-7) remains almost stable in COVID-19 patients. Despite the Ang(1-7) presence in the plasma of COVID-19 patients it seems insufficient to prevent the effects of massive AngII accumulation. These are the first direct evidence that the SARS-CoV-2 may affect the expression of blood pressure regulators with possible harmful consequences on COVID-19 outcome.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint amplification cycles were performed using a C1000 Touch Thermal cycler (Biorad, La-Coquette, France). The results of qRT-PCR were normalized using the housekeeping gene Claix, France) and the results were analyzed using a BD FACSDiva software v. 6 

The clinical characteristics of the patients included in this protocol are summarized in Table  206 I. None of the included patient had any severe or critical disease according to the WHO 207 classification (40), only 4 patients required short hospitalization and none had to be placed in 208 intensive care. All patients recovered from COVID-19 infection. Patients were divided into 209 two groups. The first group, hereafter named COVID-19 patients (patients with viral 210 persistence), was composed of 30 patients having difficulties to clear the virus and who 211 remained positive for SARS-CoV-2 after 10 days therapy with hydroxychloroquine and 5 212 days azithromycine, including 5 men and 25 women whose mean age was 49.8 and 46.2 213 years, respectively. The second group, hereafter named healed COVID-19 patients (patients 214 with rapid viral clearance), included 14 patients who had a marked decrease in their viral load 215 at day 6 after therapy, including 7 men with a mean age of 48.6 years and 7 women with a 216 mean age of 33.4 years. Samples were collected from patients and were then divided into the 217 predefined two groups. Most of the patient samples used in this study were collected between 218 1 and 3 days after the treatment had been stopped (with exception of samples from IHU_14 219 and IHU_15 patients collected 5 days after the end of treatment, and samples from IHU_17 220 and G2 patients collected respectively 7 days and 10 days after the end of treatment). A group 221 of 15 healthy volunteers was included in this study as control among which 7 males mean age 222 40.3 years and 8 females mean age 26.9 years. Samplings were performed between 13 and 14 223 days after COVID-19 diagnosis (i.e. less than 5 days after the test turned negative on the 224 nasopharyngeal sample for the COVID-19 patient group and more than 5 days after qRT-PCR 225 turned negative on nasopharyngeal sample for the healed patients group. 226 227 Reduced ACE2 mRNA expression in circulating blood cells from COVID-19 patients. 228

In order to assess the effect of SARS-CoV-2 on the ACE2 gene expression in people 229 hospitalized or having consulted for symptoms related to COVID-19 disease, we used qRT-230 PCR to compare the ACE2 mRNA expression in circulating cells from 30 COVID-19 disease 231 patients and 14 patients healed from COVID-19 with 15 healthy volunteers ( Figure 1A) . 232

When the median values of ACE2 mRNA expression were compared among groups, a 233 reduced expression of ACE2 mRNA was observed in COVID-19 patients compared to 234 healthy volunteers (median values 0.722 x 10 -3 versus 1.433 x 10 -3 ). Yet, this result appeared 235 not statistically significant according to Mann-Whitney test (p=0.0577). This tendency to 236 downregulation of ACE2 gene expression was also observed in people healed from COVID-237 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint and even accentuated compared to the COVID-19 group. The reduced expression of ACE2 239 mRNA in patients healed from COVID-19 was statistically significant according to Whitney test (p=0.0307). In addition, there were no significant differences between the two 241 groups of patients (p=0.2771). Moreover, treatment for hypertension (HT) appears to promote 242 a more rapid return to normal ACE2 gene expression since, in the healed group, patients under 243

anti-HT treatment have the closest level of ACE2 expression to the average levels of ACE2 244 mRNA expression observed in healthy volunteers. We confirmed these results by 245 investigating the expression of ACE2 mRNA in PBMCs, instead of the whole blood 246 circulating cells (the difference resides in the lack polynuclear cells in PBMCs) ( Figure 1B) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint expressed ACE2). ACE2 expression at the surface of PBMCs from patients with COVID-19 273 (n=16) and patients healed from COVID-19 (n=12), was quantified and compared to that of 274 PBMCs from healthy volunteers (n=12) (Figure 1C) . Despite the observed tendency to ACE2 275 mRNA dowregulation in PBMCs from patients (see Figure 1B Our results indicate that membrane-bound ACE2 expression is modulated among populations 294 of circulating blood cells during COVID-19 and that there was a significant decrease in the 295 expression of ACE2 mRNA and cell-surface ACE2 protein in the monocytes of patients who 296

were infected with SARS-CoV-2. 297 298

The release of soluble ACE2 (sACE2) in plasma was investigated using an ELISA assay 300 (Figure 2A) . The expression of sACE2 was found heterogeneous among the healthy control 301 group. Three patients ( code: C11, C06, and C07) of the 15 healthy controls, were found with 302 a sACE2 well above the other group members, among which a man in his 30's characterized 303 by a high expression of ACE2 mRNA. In the COVID-19 patients' group, there was also a 304 strong heterogeneity with 5 patients (code: IHU_5, IHU_8, IHU_42, IHU_21 and IHU_44), 305 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint patients were women, including two with high blood pressure, but none of them with elevated 307 expression of ACE2 mRNA. Regarding the healed group, the results were more 308

Whitney test, was that the plasma level of sACE2 which was found to be significantly 310 decreased in the COVID-19 group, compared to the healthy volunteers' group (19396 pg/mL 311 versus 22600 pg/mL; p=0.0156). It should also be noted that the healed COVID-19 group had 312 a plasma level of sACE2 of 22141 pg/mL, which was not significantly different from the 313 healthy control group (p=0.153). 314

These results strongly suggest that the significant reduction of sACE2 found in COVID-19 315 patients was a direct consequence of the SARS-CoV-2 infection and corroborated the 316 reduction in expression of ACE2 mRNA and membrane-bound ACE2. Insofar as healed 317 COVID-19 patients regain a normal level of serum sACE2 once patients had cleared their 318 virus, this molecule could be considered a biomarker of the progression of the disease with a 319 plasma decrease in patients with detectable viral load and a progressive return to normal in 320 patients with rapid virus clearance. 321 322

Since ACE2 is a key peptidase that regulates the renin-angiotensin-aldosterone system 324 (RAAS), it was of major importance to investigate the plasma level of the main peptides of 325 this pathway. The quantification of AngI, a peptide resulting from the cleavage of the 326 angiotensinogen by renin was performed as it serves as upstream precursor for AngII 327 production following hydrolysis by the ACE peptidase. In addition, since ACE2 expression 328 was found to be reduced in patients with COVID-19, it is of interest to study whether this 329 affected the plasma concentration of AngII. For this purpose, we used AngI and AngII ELISA 330 kits. The comparison of AngI levels found in healthy volunteers (median=1496 pg/mL), with 331 that from patients showed a significant increase in AngI in both COVID-19 patients (median= 332 2979 pg/mL; p=0.0029) and patients healed from COVID-19 (median= 3603 pg/mL; 333 p=0.0001) ( Figure 2B ). Next, AngII was quantified in the patient's plasma and that of the 334 healthy volunteers. This study showed that the serum AngII concentration was higher in the 335 COVID-19 patients (median= 921 pg/mL and 1038 pg/mL for COVID-19 patients and 336 patients healed from COVID-19, respectively), than in healthy volunteers (median=746 337 pg/mL) ( Figure 2C ). The differences between the two groups of patients and the healthy 338 volunteers were found to be significant according to a Mann-Whitney test (p=0,0190 and 339 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint hierarchical clustering heatmap which show that the two groups of patients behave differently 341 from the control group for all parameters studied ( Figure 2E) . It is noteworthy that the 342 plasma concentration of AngII was extremely high in two patients from the COVID-19 343 patients group. These patients were two women, respectively in their late-40's (patient code: 344 UHI_24) and mid-50's (patient code: IHU_46), without documented history of high blood 345 pressure and anti-HT treatment. Their kalemia values were also in the normal range (4.06 346 mmol/L and 4.1 mmol/L, respectively). 347

These data indicate that, in COVID-19 patients, a reduced production of ACE2 synthesis is 348 accompanied by an increase in AngII plasma levels. Since the RAAS pathway is also 349 disturbed upstream to the AngII synthesis, it can be hypothesized that the accumulation of 350

AngII is either linked to an over-production of AngI, a lower conversion rate of AngII into 351

Ang (1-7) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint 16.6% of the group. Another possible bias lies in the recruitment of patients with 83.4% 409 women in the COVID-19 group to be compared to 46.6% in the healthy control group. 410

Regarding the plasma concentration of sACE2, literature reports that males express little 411 higher ACE2 than females (46, 50). This can be linked to the finding that ACE2 is encoded by 412 a gene mapping to chromosomal position Xp22 (32), and is in agreement with the observation 413 that conversion of Ang II to Ang (1-7) by ACE2 was higher in males than females (51). 414

However, in the small number of cases studied, we found no significant difference between 415 males and females for the expression of ACE2 mRNA. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint

During the quantitative analysis of membrane ACE2 by flow cytometry, no decrease in 478

CD16 + monocytic/dendritic cells from patients. This was surprising given that there is a 480 decrease in the expression of the ACE2 transcript in PBMCs of COVID-19 patients (this 481 paper, Figure 1B) . Possibly, the downmodulation of ACE2 on PBMCs is not found due to 482 differences in the sensitivity of qRT-PCR and flow cytometry techniques. In addition, the 483 mean expression of ACE2 on the surface of PBMCs does not exceed 8-25%, which is perhaps 484 too low to measure detectable variations at the protein level. Yet we found a significant 485 decrease in membrane-bound ACE2 in a population of CD14 + /HLADR + monocytes (this 486 paper, Figure1D), that corroborates with the down regulation of ACE2 transcription in 487 adherent (monocytes) cells (this paper, Figure 1E ). It is interesting to note that this 488 conventional population of CD14 + /HLADR + monocytes increase in the PBMCs while the 489 CD14 low CD16 + inflammatory monocytes decrease as they leave the bloodstream and homing 490 tissues (including the lungs) in symptomatic COVID-19 patients (71). Moreover, we found a 491 decrease in the plasma levels of sACE2 in COVID-19 patients (this paper, Figure 2A is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint among cardiologists regarding the risk of "liaisons dangereuses" (dangerous link) between the 510 virus and its receptor and the management of patients who have hypertension (39,75,77) . The 511 medical management of hypertension involves the use of inhibitors of the renin-angiotensin-512 aldosterone system (RAAS), such as Angiotensin Converting Enzyme Inhibitors (ACEIs) and 513

Angiotensin II Receptor Blockers (ARBs), considered to upregulate the cell surface 514 expression of ACE2, with the possible adverse effects of increasing these patients' 515 susceptibility to SARS- CoV-2 (64,78) . Nonetheless, a recent study reported that ACEIs 516 reduced ACE2 expression in lungs (79). For hypertensive patients already infected with 517 SARS-CoV-2, the question has also arisen of temporarily discontinuation of the treatment 518 during COVID-19 disease to avoid viral over-replication and rapid cell-to-cell propagation of 519 the virus. Conversely, it was also considered that discontinuing treatment could also worsen 520 the general health status of patients and that maintaining treatment could have a favorable 521 effect by acting as a vasodilator, antioxidant and anti-inflammatory through the action of Ang 522

(1-7) on MAS-receptors. It is expected that when ACE2 expression is reduced, there is an 523 accumulation of AngII that activates the AT1R and AT2R receptors and increases blood 524 pressure through vasoconstriction. Here we found that the plasma concentration of AngI and 525

AngII are significantly higher in the COVID-19 patients and patients healed of COVID-19 526 than in healthy volunteers (this paper Figures 2B, 2C) . It might have seemed reasonable to 527 hypothesize that if, in COVID-19 patients, ACE2 expression was decreased and serum AngII 528 levels increased, the risk of hypertension could be increased. In the COVID-19 group, 7 out of 529 30 patients had a history of HT. We did not find a greater tendency to HT for patients who 530

were not treated for HT before the diagnosis of their COVID-19 was established. In this group 531 of patients, only two cases of HT (patient code: IHU_44 with blood pressure of 180/30 and 532 hypokalemia at 3.45 mmol/L, and IHU_46 with blood pressure of 137/65 and a kalemia of 4.1 533 mmol/L; 2/23, 8.7%), were discovered at the time of their clinical examination. In the group 534 of patients healed from COVID-19, only two (IHU-6 and IHU_27 patients) remained HT but 535 they were already known for HT prior to the discovery of their COVID-19. It is worth noting 536 that both AngI and AngII remained very high in plasma samples of patients even after the 537 virus was apparently cleared from patients. 538

The decreased expression of ACE2 was consistent with the observed accumulation of AngII 539 in COVID-19 patients. Therefore, it may be surprising to find no significant difference 540 between the three groups studied with respect to the quantification of the Ang(1-7) plasma 541 levels. In particular, we noted strong Ang(1-7) expression in three COVID-19 patients 542 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint with HT, expressed the highest plasma level of AngII; patient IHU_8, a woman in her early-544 80's with HT, expressed a very high plasma level of sACE2, while the patient IHU_13 was a 545 man in his early-50's with no known history of HT. The reduction in transcription of the 546 ACE2 gene should result in a reduced capacity to cleave AngII to Ang (1-7) . However, Ang 547

(1-7) production did not collapsed in COVID-19 patients and tended to be slightly higher than 548 in healthy volunteers. It cannot be excluded that ACE2 mRNA expression in PBMCs is 549 valuable for this tissues only and that ACE2 may remain expressed on some cell types leading 550 to cleavage of AngII that accumulates in excess COVID-19 patients to produce Ang (1-7) 551 (80). We found (this paper, Figures 1, S1 ) that cell-surface expression of ACE2 can be 552 differentially modulated in cellular populations. However, it is much more likely that an 553 alternative pathway for the biosynthesis of Ang (1-7), independent of ACE2, can contribute to 554 the biosynthesis of Ang(1-7). The comparison of intrarenal AngI, AngII and Ang(1-7) in wild 555 type mice and tisACE -/mice lacking the ACE, revealed that the AngI and AngII levels were 556 decreased by 80% in tisACE -/mice, whereas the Ang(1-7) levels were sustained (81). It was 557 also reported that Ang(1-7) can be formed directly from AngI through a pathway that is 558 independent of AngII production using the endopeptidases neprilysin (NEP), a 95 kDa 559 membrane-anchored metalloendopeptidase located on the vascular surface of blood vessels 560 and thimet oligopeptidase (TOP), a 80KDa soluble metalloendopeptidase, which both 561 hydrolyzes Ang I decapeptide at the Pro-Phe bond to form Ang(1-7) (82-84). This suggests 562 that in COVID-19 patients the balance between AngII and Ang(1-7) is more complex than 563 previously assumed since the plasma levels of AngII are high but the levels of Ang(1-7) do 564 not drop down. This should be further studied, as Ang(1-7) generation was previously 565 reported capable to achieve protection against AngII-mediated lung injury and cardiovascular 566 risks (77,85,86). However, the plasma levels of AngII in COVID-19 is probably too high so 567 that its harmful effects are offset by the action of Ang(1-7) . Moreover, it is likely that the 568 increase in AngII mediate a dysregulation of the RAAS axis, with AngII-induced 569 overproduction of aldosterone through AT1 receptor stimulation which may be at least in part 570 responsible of the hypokaliemia observed in some COVID-19 patients (e.g. patient IHU_44), 571 as recently reported elsewhere (87) . 572

In conclusion, we have demonstrated here for the first time that during the COVID-19 573 disease, a decrease in ACE2 mRNA expression, ACE2 cell-surface protein and plasma level 574 of sACE2, is observed. As a result, the plasma levels of AngII increase due to the absence of 575 metabolism of AngII to Ang (1-7). However, this has no direct impact on the plasma levels of 576 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint pathway is less efficient or totally ineffective, Ang(1-7) is probably produced by metabolism 578 of AngI to Ang (1) (2) (3) (4) (5) (6) (7) , likely by the neprilysin and/or thimet oligopeptidase. The high plasma 579 concentration of AngI in COVID-19 patients should favor this pathway. Although the plasma 580 concentration of Ang(1-7) remains elevated in COVID-19 patients, it appears to be 581 insufficient to prevent the harmful effects of AngII that accumulates in COVID-19. Finally 582 we also report preliminary evidence that being on anti-HT treatment seems to be beneficial 583 since, in the group of patients healed from COVID-19, those on anti-HT treatment were those 584 who had the closest average ACE2 expression levels to the average ACE2 mRNA expression 585 levels observed in healthy volunteers, suggesting a more rapid return to normal is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint

We are grateful to all the clinical, technical and paramedical staffs of the hospitalization units 612 and laboratories for their expert assistance. We thank the students and our colleagues from the 613 Mediterranean Infection IHU who volunteered to join the healthy control group. We thank 614

Aissatou Bailo-Diallo, Orlane Soldani, Andriamiharimamy Rajaonison and Youssouf Sérémé 615 for helpful technical discussions. We thank the Cookie Trad company for English editing. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 10, 2021. ; https://doi.org/10.1101/2021.02.08.21251001 doi: medRxiv preprint

A pneumonia outbreak 647 associated with a new coronavirus of probable bat origin

Bats, Coronaviruses, and Deforestation: Toward the 651 Emergence of Novel Infectious Diseases?

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

The 659 genome sequence of the SARS-associated coronavirus

Isolation and 663 characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

A Novel Coronavirus from Patients 667 with Pneumonia in China

Clinical course and outcomes of critically 671 ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, 672 observational study

COVID-19 : The conjunction of 676 events leading to the pandemic and lessons to learn for future threats

Clinical features of patients infected 680 with 2019 novel coronavirus in Wuhan

A novel 684 coronavirus associated with severe acute respiratory syndrome

Dysregulation of immune response 688 in patients with COVID-19 in Wuhan, China

Incidence of venous thromboembolism in hospitalized patients with COVID-19

COVID-19 Patients on CT Angiography and Relationship to D

Dimer Levels

Acute pulmonary 700 embolism in COVID-19 disease: Preliminary report on seven patients

D-dimer is Associated with Severity of Coronavirus Disease 2019: 704 A Pooled Analysis

Advances in the research 707 of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the 708 corresponding therapeutic measures

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-713 centre descriptive study

It 717 is infection or rather vascular inflammation? Game-changer insights and recommendations 718 from patterns of multi-organ involvement and affected subgroups in COVID-19

Attention should be paid to 722 venous thromboembolism prophylaxis in the management of COVID-19

Anticoagulant treatment is associated with 726 decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Receptor and viral determinants 730 of SARS-coronavirus adaptation to human ACE2

SARS-CoV-2 by full-length human ACE2

Predicting the angiotensin 738 converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. Microbes

Tissue distribution of 742 ACE2 protein, the functional receptor for SARS Coronavirus

Single-cell RNA expression profiling 746 of ACE2, the receptor of SARS-CoV-2

Counterregulatory actions 754 of angiotensin-(1-7)

A human homolog of 757 angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive

Exploring the structure and function of zinc metallopeptidases: old enzymes 761 and new discoveries

The role of ACE2 in cardiovascular 764 physiology

Molecular mechanisms of inhibition of vascular growth by 768 angiotensin-(1-7)

A novel 772 angiotensin-converting enzyme-related carboxypeptidase. (ACE2) converts angiotensin I to 773 angiotensin 1-9

Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging

Angiotensin converting 780 enzyme-2 confers endothelial protection and attenuates atherosclerosis

Human 784 recombinant soluble ACE2 in severe COVID-19

Differential Downregulation of ACE2 by the Spike 789 Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63

SARS coronavirus-induced lung injury

Increasing host 797 cellular receptor-angiotensin converting enzyme 2 (ACE2) expression by coronavirus may 798 facilitate 2019-nCoV (or SARS-CoV-2) infection

ACE2 receptor polymorphism : susceptibility to

SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Coronavirus disease 2019

SARS-CoV-2 by full-length human ACE2

Renin-Angiotensin-Aldosterone System inhibitors in patients with Covid-19

Renin-angiotensin system inhibitors 920 improve the clinical outcomes of COVID-19 patients with hypertension

Treatment with ACE-inhibitors is associated with 924 less severe disease with SARS-Covid-19 infection in a mult-site UK acute Hospital trust

Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and 929

Clinical Outcomes in COVID-19 Patients With Hypertension

Association of COVID-19 inflammation with activation of the C5a-C5aR1axis

Necrosis Factor-Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the

Angiotensin-939 converting Enzyme-2 (ACE2)

Differential Downregulation of ACE2 by the Spike 944 Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. 945 converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide 982 metabolism

Angiotensin II-independent angiotensin-(1-7) formation in rat hippocampus: involvement of 986 thimet oligopeptidase

The Angiotensin-(1-7) Axis: Formation and Metabolism Pathways

Angiotensin-(1-7) Springer

Vascular inflammation and the renin-angiotensin 998 system

Hypokalemia in 1002 Patients with COVID-19. medRxiv preprint not peer reviewed

Expression of ACE2 mRNA in circulating blood cells (both mononuclear and polynuclear 1020 cells) from the group of patients with COVID-19 (n = 30) or patients healed from COVID-19 1021 (n = 14) compared to a healthy volunteers control group (n= 15). The results are expressed as 1022 log10 RQ were RQ = 2 (−ΔCT) . B. Expression of ACE2 mRNA in PBMCs samples from the 1023 three different groups studied: patients with COVID-19 (n = 8), patients healed from COVID-1024 19 (n = 10), and healthy volunteers

The upper panels show the 1027 gating parameter chosen (from individual to individual, between 8 and 35% of PBMCs 1028 express ACE2 at their surface), the lower left panel indicates the percent of cells expressing 1029 ACE2 while the lower right panel is an histogram representing the mean fluorescence 1030 intensity (MFI). D. Flow cytometry analysis of ACE2 protein expression at the surface of 1031 different cell populations during COVID-19. The gating (upper panels) was performed using 1032 different cluster differentiation-specific mAb (CD14, CD16, HLA-DR). The figure illustrates 1033 the results obtained with the HLA-DR + /CD14 + population while data obtained with respect to 1034 other cell populations are presented in the supplementary figure S1

-PCR analysis of ACE2 mRNAs expression in monocytes cells from COVID-19

= 6) and patients healed from COVID-19 (n = 6) versus monocytes cells from 1038 healthy donors (n = 6). The data are expressed as log10 RQ were RQ = 2 (−ΔCT)

Whitney test used for the statistical analysis